

## **INFUSION & MEDICAL CENTER**

| 1.Patient Name  Patient demographic and insuran                               | DOB   | Patient Phone/Cell #         |
|---|---|------------------------------|
|   |   |                              |
| 2.Medical Information (Please select pr<br>Primary Diagnosis: Crohn's Disease | lmary diagnosis and comp                    | ICD-10 Code;:                |
| · -   |   |                              |
| Psoriasis,<br>Ulcerative Colitis  |   | ICD-10 Code: L40             |
|   |   | ICD-10 Code:                 |
| Allergies:Other   |   |                              |
| 3.Clinical Information – Please fax with                                      |   |                              |
| <ul> <li>Clinical notes, labs, test supporting primary d</li> </ul>           | iagnosis                                    | Patient                      |
| Pre-Screening Documentation   | 3   | Weight: lbs.                 |
| o Hepatitis B Screening Results (including Hep                                | o B surface antigen)                        | <b>Height:</b> in.           |
| o TB Screening Results  |   |                              |
| Previous Drug Therapy History, including the                                  | •   |                              |
| □ Remicade □ Orencia □ Humria □ Cimz  |   |                              |
| ☐ Washout period of weeks desired   | d prior to the initiation of this ord       | lered therapy                |
| STEL  | ARA® (ustekinumab)                          |                              |
| Drug Order:   | -   |                              |
| 4. New Start  |   |                              |
| ☐ Psoriasis   |   | # Refills (Recommend 3)      |
| Administer 45 mg Stelara subcutaneou  | sly on week 0, week 4 and then e            | every 12 weeks thereafter    |
| ☐ Administer 90 mg Stelara subcutaneou  | ısly on week 0, week 4 and then e           | every 12 weeks thereafter    |
| ☐ Crohn's Disease & Ulcerative Colitis  | •   | ·                            |
| Administer mg Stelara IV over 1 h   | our x 1 dose                                |                              |
| Maintenance Therapy   |   |                              |
| ☐ Psoriasis   |   | # Refills (Recommend 3)      |
| Administer 45 mg Stelara subcutaneou  | sly every 12 weeks thereafter               |                              |
| Administer 90 mg Stelara subcutaneou  | sly every 12 weeks thereafter               |                              |
| Crohn's Disease & Ulcerative Colitis  |   | # Refills (Recommend 3)      |
| Administer 90 mg Stelara subcutaneously                                       | 8 weeks after the initial infusion          | and every 8 weeks thereafter |
| Adverse Drug Reaction Protocol: Manage any a                                  | dverse reaction that may occur p            | oer approved ADR Protocol.   |
| Pre-Medication Orders:  |   |                              |
| No Pre-medications are r  | recommended based on manufacturer g         | juidelines.                  |
| By signing this form and ut   | ilizing these services, I am authorizing In | ntramed Plus                 |
| • •   | on agent with medical and pharmacy ins      | ·                            |
| 5. Physician Signature:   |   |                              |
| Dispense as writte  |   |                              |
| Printed Physician's Name with Credentials:                                    |   | Phone #:                     |
| FAX ALL INFORMATION   | CENTR                                       | AL INTAKE PHONE              |
| CENTRAL FAX <b>803.999.1754</b>   |   | 3.999.1750                   |
| CENTRAL FAX OUS. 333.1734   | 00  |                              |